Tafluprost
Tafluprost, Zioptan (tafluprost) is a small molecule pharmaceutical. Tafluprost was first approved as Zioptan on 2012-02-10. It is used to treat open-angle glaucoma in the USA. The pharmaceutical is active against prostaglandin F2-alpha receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| eye diseases | D005128 |
Trade Name
FDA
EMA
Tafluprost, Zioptan (discontinued: Tafluprost)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Tafluprost
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZIOPTAN | Thea Pharma | N-202514 RX | 2012-02-10 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| tafluprost | ANDA | 2022-06-09 |
| tafluprost ophthalmic | NDA authorized generic | 2022-06-01 |
| zioptan | New Drug Application | 2024-04-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| open-angle glaucoma | EFO_0004190 | D005902 | H40.1 |
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
36 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glaucoma | D005901 | EFO_0000516 | H40 | 2 | 3 | 11 | 14 | 6 | 34 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | 2 | 1 | 9 | 9 | 4 | 24 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | 9 | 9 | 4 | 23 |
| Hypertension | D006973 | EFO_0000537 | I10 | 2 | 1 | 8 | 5 | 3 | 18 |
| Graves ophthalmopathy | D049970 | EFO_1001466 | — | — | — | — | 1 | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | — | — | — | 1 | — | 1 |
| Thyroid diseases | D013959 | HP_0000820 | E00-E07 | — | — | — | 1 | — | 1 |
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | — | 1 | — | — | — | 1 |
| Cataract | D002386 | HP_0000518 | H26.9 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Corneal diseases | D003316 | — | H18.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Tafluprost |
| INN | tafluprost |
| Description | Tafluprost (trade names Taflotan by Santen Pharmaceutical, Zioptan by Merck in the US and Saflutan by Mundipharma in Australia) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension, alone or in combination with other medication. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.
|
| Classification | Small molecule |
| Drug class | prostaglandins |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)OC(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/C(F)(F)COc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 209860-87-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1963683 |
| ChEBI ID | 66899 |
| PubChem CID | 6433101 |
| DrugBank | DB08819 |
| UNII ID | 1O6WQ6T7G3 (ChemIDplus, GSRS) |
Target
Agency Approved
PTGFR
PTGFR
Organism
Homo sapiens
Gene name
PTGFR
Gene synonyms
NCBI Gene ID
Protein name
prostaglandin F2-alpha receptor
Protein synonyms
FP prostanoid receptor, PGF receptor, PGF2 alpha receptor, prostaglandin receptor (2-alpha), Prostanoid FP receptor
Uniprot ID
Mouse ortholog
Ptgfr (19220)
prostaglandin F2-alpha receptor (P43117)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Zioptan – Akorn
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 766 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,993 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use